#United States #New York #CurePSP #PSP #Kristophe Diaz

CurePSP Enhances Leadership Amid Remarkable Growth

CurePSP, a prominent nonprofit dedicated to researching and advocating for neurodegenerative diseases like progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA), is making significant leadership changes in light of an unprecedented year of growth. The organization has recently appointed Kristophe Diaz, PhD, as its new Chief Executive Officer and welcomed Stephen E. Canter and Salin Geevarghese to its Board of Directors.

A Year of Milestones

The past fiscal year marked the most successful in CurePSP's 35-year history, signifying an exciting phase for the organization. Under the direction of Kristophe Diaz, who was previously the executive director and chief scientific officer, CurePSP has strengthened its commitment to raising awareness and building support systems while advancing research. With the incorporation of Canter and Geevarghese, the organization aims to amplify its impact tremendously.

An Empowered Leadership Team

The newly appointed board members bring valuable experience and insights that will bolster CurePSP's mission. Stephen E. Canter arrives at CurePSP with a profound personal connection, as he is driven by his late wife’s battle with PSP. His extensive background in investment management will help steer the organization towards achieving its funding goals and enhancing its overall impact in the field.

Salin Geevarghese, who tragically lost his parents to Alzheimer's and CBD, underscores his commitment towards leveraging his personal experiences to improve the lives of others affected by these diseases. As president and CEO of SGG Insight, LLC, he brings significant expertise in social inclusion and policy engagement, which he believes will further CurePSP's initiatives.

Focus on Research and Advocacy

Under Diaz's leadership, CurePSP aims to push the envelope in neurodegenerative disease research and advocacy. Diaz remarked, “Promoting Dr. Kristophe Diaz to CEO and welcoming Steve Canter and Salin Geevarghese to our board strengthens our leadership at a pivotal moment. Their vision, experience, and passion will accelerate our momentum.”

This shift in leadership aligns with the organization’s ongoing projects, such as the PSP Trial Platform (PTP), a first-of-its-kind clinical trial initiative partnered with the University of California, San Francisco, set to evaluate multiple treatments for PSP in a concurrent manner. Additionally, the launch of the CurePSP Genetics Program, which facilitates genetic sample collection, seeks to deepen the understanding of PSP, CBD, and MSA, fostering advancements in treatment protocols aimed at improving patient outcomes.

Moreover, expanding the Quality of Life Respite Care Fund is another critical initiative aiming to provide more families with access to necessary support services that facilitate caregiving in the home environment.

Commitment to a Cure

CurePSP's strategic focus continues to align with its larger mission of finding a cure and enhancing the quality of life for patients and their families. The integration of these leadership advancements demonstrates the organization’s commitment to being at the forefront of research and advocacy efforts.

The synergy of Michael Canter’s and Salin Geevarghese’s personal experiences and professional backgrounds positions CurePSP for continued success in its endeavors, helping those living with PSP, CBD, and MSA.

About CurePSP

Founded with the goal of raising awareness and finding cures for PSP, CBD, and MSA, CurePSP is recognized as a leading nonprofit organization in this field. The commitment of its team, supported by research and education initiatives, plays a crucial role in improving care delivery and community support for affected families. The organization is designated as a registered 501(c)(3) charity in the United States, ensuring its dedication to transparency and community impact.

With a renewed leadership approach, CurePSP embarks on an influential journey to improve the lives of individuals and families affected by neurodegenerative diseases, fueled by hope, community engagement, and scientific excellence.